Enzalutamide in the treatment of metastatic castrate-sensitive prostate cancer

Abstract

The treatment landscape for metastatic castrate-sensitive prostate cancer has changed dramatically in the past decade because of the approval of chemotherapy and novel androgen therapies in combination with androgen deprivation therapy. The addition of these agents has resulted in overall benefits and progression-free survival for patients. The National Institute for Health and Care Excellence recently approved enzalutamide in the treatment of metastatic castrate-sensitive prostate cancer. Oncology nurse prescribers are central to the care of prostate cancer, providing holistic assessment and management of the disease and treatment side effects. A comprehensive understanding of the mechanism of action and specific side effects of androgen receptor inhibitors will enable an oncology nurse to provide timely interventions with a high standard of care.